1
|
Almdallaleh SA, Alsuwaida AO, Altalhi AM, ALJayar DM, Massad EE, Hamid MM, Jaganathan PP, Al-Hababi FH. Renin-angiotensin-system blockers and IgG antibodies in end-stage renal disease hemodialysis-receiving patients diagnosed with COVID-19 infection. Saudi Med J 2023; 44:875-881. [PMID: 37717960 PMCID: PMC10505288 DOI: 10.15537/smj.2023.44.9.20230129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 08/01/2023] [Indexed: 09/19/2023] Open
Abstract
OBJECTIVES To evaluate the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections among patients receiving in-center hemodialysis (ICHD), the relationship between the IgG antibody levels against the virus and SARS-CoV-2-associated symptoms, hemodialysis adequacy, and the antihypertensives used in order to control blood pressure. METHODS A prospective observational study was carried out at a tertiary care center, King Fahad Kidney Center, Riyadh, Kingdom of Saudi Arabia, between November 2020 and January 2021. A total of 214 ICHD patients with end-stage renal disease (ESRD) were included, and the levels of their anti-SARS-CoV-2 IgG antibodies were assessed after obtaining their informed consent. RESULTS Our tests indicated that 15% of the patients in the study's population had detectable SARS-CoV-2 IgG antibodies, with more than half of them (53%) being asymptomatic. We also found that ESRD patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had higher levels of SARS-CoV-2 IgG antibodies than patients not receiving this group of medications. CONCLUSION More studies are required to assess whether patients with a SARS-CoV-2 infection that do not have an indication for being prescribed ACEIs/ARBs would benefit from receiving these medications.
Collapse
Affiliation(s)
- Sultan A. Almdallaleh
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Abdulkareem O. Alsuwaida
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Abdulhadi M. Altalhi
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Dina M. ALJayar
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Elzibair E. Massad
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Mazaher M. Hamid
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Parameaswari P. Jaganathan
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| | - Fadel H. Al-Hababi
- From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia
| |
Collapse
|